8-K: Recursion Pharmaceuticals Reports Q3 2024 Results and Advances Exscientia Merger

Recursion Pharmaceuticals announced its third quarter 2024 financial results, highlighted by a $30 million option agreement with Roche-Genentech and progress towards its merger with Exscientia.

Summary

• Recursion Pharmaceuticals reported its third quarter 2024 financial results, with total revenue of $26.1 million, a significant increase from $10.5 million in the same quarter of 2023.
• The revenue increase was primarily driven by a $30 million option fee from Roche-Genentech for a neuroscience phenomap.
• Research and development expenses rose to $74.6 million, up from $70.0 million in the third quarter of 2023, due to platform and personnel costs.
• General and administrative expenses increased to $37.8 million, compared to $29.2 million in the prior year, mainly due to higher software and lease expenses.
• The company's net loss was $95.8 million for the quarter, slightly higher than the $93.0 million loss in the third quarter of 2023.
• Net cash used in operating activities was $59.2 million, an improvement from $72.9 million in the same period last year, due to the $30 million acceptance fee.
• As of September 30, 2024, Recursion had $427.6 million in cash and cash equivalents.
• The company is progressing towards its business combination with Exscientia, with a shareholder meeting scheduled for November 12, 2024, and an expected scheme of arrangement date of November 20, 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant progress in partnerships, clinical trials, and the Exscientia merger. However, the increased net loss and operating expenses temper the overall sentiment, indicating a need for continued financial discipline.

Positives

• The $30 million option fee from Roche-Genentech validates Recursion's scientific approach and ability to deliver on success-based data options.
• The expanded collaboration with Google Cloud will leverage advanced technologies to support Recursion's drug discovery platform.
• The Phase 2 trial for REC-994 in CCM showed encouraging trends in efficacy, indicating potential for future development.
• The company has a strong cash position of $427.6 million, providing financial stability.
• The business combination with Exscientia is progressing rapidly, ahead of original guidance.
• Multiple clinical trial milestones were achieved, including positive data and trial initiations.

Negatives

• The net loss for the quarter was $95.8 million, slightly higher than the $93.0 million loss in the same quarter of 2023.
• Research and development expenses increased to $74.6 million, indicating higher operational costs.
• General and administrative expenses also increased to $37.8 million, driven by higher software and lease expenses.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Challenges inherent in pharmaceutical research and development, including the timing and results of clinical programs, pose a risk.
• The company's ability to obtain financing for development activities and other corporate purposes is a risk.
• The success of collaboration activities and the ability to obtain regulatory approval of drug candidates are not guaranteed.
• The proposed business combination with Exscientia is subject to various closing conditions and may not be completed.
• The company faces risks related to cyberattacks, disruptions to technology systems, and the ability to retain key employees.

Future Outlook

The company expects to close the proposed business combination with Exscientia in November 2024 and anticipates a preliminary readout for the C. difficile infection trial by the end of 2025. They also expect to share Phase 2 safety and preliminary efficacy data for FAP and AXIN1/APC mutant cancers in H1 2025 and an update on the NF2 trial in Q4 2024. An IND submission for a fibrosis target is expected in early 2025.

Management Comments

• Chris Gibson, Ph.D., Co-founder and CEO of Recursion, stated that they are excited to drive rapidly towards the closure of the proposed business combination with Exscientia.
• He believes the combination with Exscientia will help to build a robust and diverse portfolio of tech-enabled clinical programs.
• He also expressed confidence in the company's ability to translate their work into potential medicines for patients.

Industry Context

This announcement highlights the growing trend of TechBio companies leveraging technology and data to accelerate drug discovery. The collaboration with Google Cloud and the merger with Exscientia demonstrate Recursion's commitment to integrating advanced technologies and expanding its capabilities. The focus on multiple clinical programs and partnerships reflects the industry's move towards diversified pipelines and collaborative approaches.

Comparison to Industry Standards

• Recursion's $30 million upfront payment for the neuroscience phenomap from Roche-Genentech is a significant deal, comparable to other major biotech partnerships in early-stage drug discovery.
• The company's focus on using AI and machine learning for drug discovery aligns with industry trends, with companies like Insitro and Atomwise also leveraging these technologies.
• The clinical trial progress, including the Phase 2 results for REC-994 and the initiation of other trials, is consistent with the timelines of other clinical-stage biotech companies.
• The merger with Exscientia is a strategic move to combine complementary capabilities, similar to other mergers in the biotech space aimed at creating a more comprehensive platform.
• The cash position of $427.6 million is relatively strong for a company of this stage, providing a runway for further development, although the burn rate is also high.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the proposed merger with Exscientia and the potential for future value creation.
• Employees may experience changes due to the merger and the company's growth.
• Patients may benefit from the development of new therapies for various diseases.
• Partners will be impacted by the ongoing collaborations and the potential for future deals.
• Creditors will be impacted by the company's financial performance and cash position.

Next Steps

• The company will hold a special shareholder meeting on November 12, 2024, to vote on the proposed combination with Exscientia.
• The scheme of arrangement for the Exscientia merger is expected on November 20, 2024.
• Recursion plans to meet with the FDA to discuss the development of REC-994 for CCM.
• The company will present Phase 2 data for REC-994 at a medical conference and publish results in a peer-reviewed journal.
• They expect to share an update on the NF2 trial in Q4 2024.
• Phase 2 safety and preliminary efficacy data for FAP and AXIN1/APC mutant cancers are expected in H1 2025.
• A preliminary readout for the C. difficile infection trial is expected by the end of 2025.
• An IND submission for a fibrosis target is expected in early 2025.
• Phase 1/2 dosing for REC-1245 is expected to initiate in Q4 2024.

Key Dates

Keywords

drug discovery, clinical trials, biopharma, genomics, artificial intelligence, machine learning, partnerships, merger, oncology, neuroscience, rare disease, small molecule, technology, data, RBM39, CCM, C. difficile, Exscientia, Roche-Genentech, Google Cloud